Should I buy or sell MiNK Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INKT shares. View INKT analyst ratings or view top-rated stocks .

What is MiNK Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month price objectives for MiNK Therapeutics' stock. Their INKT share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 932.5% from the stock's current price. View analysts price targets for INKT or view top-rated stocks among Wall Street analysts .

How have INKT shares performed in 2024?

MiNK Therapeutics' stock was trading at $1.07 at the beginning of the year. Since then, INKT shares have decreased by 18.5% and is now trading at $0.8717. View the best growth stocks for 2024 here .

Are investors shorting MiNK Therapeutics?

MiNK Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 41,100 shares, a decrease of 11.6% from the March 15th total of 46,500 shares. Based on an average trading volume of 99,400 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.4% of the shares of the stock are sold short. View MiNK Therapeutics' Short Interest .

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our INKT earnings forecast .

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its earnings results on Thursday, March, 21st. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01.

When did MiNK Therapeutics IPO?

MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free INKT Stock Alerts

$0.87

-0.04 (-4.39%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.87
▼
$0.96
50-Day Range: $0.86
▼
$1.56
52-Week Range: $0.75
▼
$3.34

Volume: 42,419 shs
Average Volume: 91,714 shs
Market Capitalization: $30.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.00

Get MiNK Therapeutics alerts:

MiNK Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 932.5% Upside
$9.00 Price Target
Short Interest: Healthy
0.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.59) to ($0.58) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.06 out of 5 stars

Medical Sector

341st out of 918 stocks

Biological Products, Except Diagnostic Industry

48th out of 147 stocks

3.5

Analyst's Opinion

Consensus Rating
MiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
MiNK Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.42% of the float of MiNK Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
MiNK Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MiNK Therapeutics has recently decreased by 11.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MiNK Therapeutics does not currently pay a dividend.
Dividend Growth
MiNK Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INKT.

3.8

News and Social Media Coverage

News Sentiment
MiNK Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 0 articles on an average week.
Search Interest
2 people have searched for INKT on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.81% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.87% of the stock of MiNK Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MiNK Therapeutics are expected to grow in the coming year, from ($0.59) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MiNK Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MiNK Therapeutics is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About MiNK Therapeutics Stock (NASDAQ:INKT)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INKT Stock News Headlines

April 16, 2024 | americanbankingnews.com

MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Down 11.6% in March

April 11, 2024 | finance.yahoo.com

This MiNK Therapeutics Insider Increased Their Holding In The Last Year

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 8, 2024 | globenewswire.com

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

March 25, 2024 | markets.businessinsider.com

Buy Rating for MiNK Therapeutics Amidst Promising AGENT-797 Progress and Strategic Financial Moves

March 22, 2024 | insidermonkey.com

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript

March 21, 2024 | markets.businessinsider.com

Promising Clinical Progress and Market Potential for MiNK Therapeutics’ agenT-797 in Gastric Cancer Study

March 21, 2024 | investorplace.com

INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | globenewswire.com

MiNK Reports Fourth Quarter and Year-End 2023 Results

March 20, 2024 | benzinga.com

Earnings Outlook For MiNK Therapeutics

March 8, 2024 | finanznachrichten.de

MiNK Therapeutics: MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

March 7, 2024 | globenewswire.com

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

March 6, 2024 | globenewswire.com

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

February 24, 2024 | msn.com

Cell therapy could help patients with ARDS from severe Covid-19, study involving ARU shows

February 14, 2024 | finance.yahoo.com

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

February 6, 2024 | finance.yahoo.com

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

January 30, 2024 | finance.yahoo.com

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

December 20, 2023 | markets.businessinsider.com

ImmunoScape, MiNK Therapeutics Join To Develop Next-generation TCR Therapies

December 20, 2023 | finance.yahoo.com

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

November 22, 2023 | morningstar.com

MiNK Therapeutics Inc INKT

November 9, 2023 | msn.com

MiNK Therapeutics GAAP EPS of -$0.15

November 9, 2023 | finance.yahoo.com

MiNK Therapeutics Reports Third Quarter 2023 Results

November 9, 2023 | finance.yahoo.com

MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges

November 3, 2023 | finance.yahoo.com

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

November 3, 2023 | finance.yahoo.com

MiNK Therapeutics Insider Ups Holding During Year

October 30, 2023 | finance.yahoo.com

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

See More Headlines

Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:INKT
CUSIP: N/A
CIK: 1840229
Web: www.minktherapeutics.com
Phone: 212-994-8250
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.00
High Stock Price Target: $9.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +932.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.66)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -220.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.32
Quick Ratio: 0.32

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.52) per share
Price / Book: -1.68

Miscellaneous

Outstanding Shares: 34,699,000
Free Float: 28,519,000
Market Cap: $30.25 million
Optionable: No Data
Beta: 0.13

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Garo H. Armen Ph.D. (Age 71)
Executive Chairman
Dr. Jennifer S. Buell Ph.D. (Age 49)
President, CEO & Director
Comp: $812.78k
Dr. Marcus Antonius van Dijk Ph.D. (Age 62)
Chief Scientific Officer
Comp: $369.92k
Ms. Christine M. Klaskin (Age 58)
Treasurer
Comp: $27.24k
Ms. Heather Boussios
General Counsel & Chief Compliance Officer
Joy Zhou Ph.D.
Vice President & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INKT Stock Analysis - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INKT shares.
View INKT analyst ratings or view top-rated stocks.
What is MiNK Therapeutics' stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price objectives for MiNK Therapeutics' stock. Their INKT share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 932.5% from the stock's current price.
View analysts price targets for INKT or view top-rated stocks among Wall Street analysts.
How have INKT shares performed in 2024?: MiNK Therapeutics' stock was trading at $1.07 at the beginning of the year. Since then, INKT shares have decreased by 18.5% and is now trading at $0.8717.
View the best growth stocks for 2024 here.
Are investors shorting MiNK Therapeutics?: MiNK Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 41,100 shares, a decrease of 11.6% from the March 15th total of 46,500 shares. Based on an average trading volume of 99,400 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.4% of the shares of the stock are sold short.
View MiNK Therapeutics' Short Interest.

When is MiNK Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our INKT earnings forecast.
How were MiNK Therapeutics' earnings last quarter?: MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its earnings results on Thursday, March, 21st. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01.
When did MiNK Therapeutics IPO?: MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.
How do I buy shares of MiNK Therapeutics?: Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INKT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MiNK Therapeutics (INKT) Stock Price, News & Analysis

MiNK Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MiNK Therapeutics Stock (NASDAQ:INKT)

INKT Stock Price History

INKT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

INKT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™